- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
- S-4/A Registration of securities issued in business combination transactions
- 8.1 October 1, 2021
- 8.2 Opinion of Goodwin Procter LLP As to Certain U.S. Federal Tax Matters
- 10.4 Incentive Stock Option Grant Notice
- 10.5 Form of Non-employee Director Compensation Policy
- 10.6 Senior Executive Cash Incentive Bonus Plan
- 10.7 Severance and Change In Control Policy
- 10.8 Amended and Restated Employment Letter Agreement
- 10.9 Employment Letter Agreement
- 10.10 Eric Hedrick, M.D
- 10.12 Amended and Restated Employment Letter Agreement
- 10.13 Founder Agreement
- 10.14 Form of Director Indemnification Agreement
- 10.15 Form of Officer Indemnification Agreement
- 10.16 Lease Agreement
- 10.17 Sublease Agreement
- 10.18 Exclusive License Agreement by and Between Cstone Pharmaceuticals and Eqrx, In
- 10.19 Strategic Collaboration and License Agreement
- 23.1 Consent of Withumsmith+brown, PC
- 23.2 Consent of Ernst & Young LLP
- 99.10 Consent to Reference In Proxy Statement/prospectus
- 99.11 Consent of Houlihan Loukey Capital, Inc.
- Download Excel data file
- View Excel data file
- 2 Dec 21 EFFECT Notice of effectiveness
- 1 Dec 21 424B3 Prospectus supplement
- 30 Nov 21 S-4/A Registration of securities issued in business combination transactions (amended)
- 23 Nov 21 S-4/A Registration of securities issued in business combination transactions (amended)
- 29 Oct 21 S-4/A Registration of securities issued in business combination transactions (amended)
-
1 Oct 21 S-4/A Registration of securities issued in business combination transactions (amended)
- 25 Aug 21 S-4 Registration of securities issued in business combination transactions
Exhibit 99.10
October 1, 2021
CM LIFE SCIENCES III, INC.
c/o Corvex Management LP
667 Madison Avenue
New York, New York 10065
Consent to Reference in Proxy Statement/Prospectus
CM Life Sciences III, Inc. (the “Company”) is filing a Registration Statement on Form S-4 (the “Registration Statement”) with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”). In connection therewith, I hereby consent, pursuant to Rule 438 of the Securities Act, to the reference to me in the proxy statement/prospectus included in the Registration Statement and any and all amendments and supplements thereto as a member of the board of directors of the Company following the consummation of the business combination as described in the proxy statement/prospectus.
Sincerely, | ||
/s/ Kathryn Giusti | ||
Name: | Kathryn Giusti |